With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...